BackAurobindo Pharma posts `91.8 crore profit in December
Revenue from operations rose 22% to `1,570 crore from `1,284.51 crore on new product launches in the US
PremiumHyderabad: Higher sales on the back of new product launches in the US market helped Hyderabad-based drug maker Aurobindo Pharma Ltd post a profit after tax of ₹ 91.8 crore in the quarter ended 31 December on a consolidated basis, against a loss of ₹ 28.5 crore in the year-ago period.
Revenue from operations rose 22% to ₹ 1,570 crore from ₹ 1,284.51 crore.
“We continue to see traction on our performance both in sales and earnings on a year-on-year basis on account of improved business mix in formulations from new product approvals and launches in the US market," managing director N. Govindarajan said in a statement.
“These will pave the way for consolidating the injectable formulations business," the company said.
Aurobindo got approvals to launch 11 new generic products in the US market in the third quarter.
The results were announced after the close of market hours on Thursday.
Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!
